A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
